M
HOWL icon

Murchinson’s Werewolf Therapeutics HOWL Stock Holding History

Murchinson’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-62,500
Closed -$153K – 99
2024
Q2 		$153K Buy
+62,500
New +$300K 0.02% 57

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Murchinson's HOWL Position: Q3 2024 in Review

Murchinson sold out of Werewolf Therapeutics (HOWL) in Q3 2024, closing a stake of 62,500 shares — an estimated $153K sold.

Murchinson first reported a position in HOWL in Q2 2024 and held it in 1 quarter. The position peaked at $153K in Q2 2024. 69 funds tracked by Wall St. Rank hold HOWL as of Q3 2024.

  • Murchinson reported no remaining Werewolf Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Murchinson sold 62,500 Werewolf Therapeutics shares in Q3 2024, an estimated $153K.
  • Murchinson first reported a position in Werewolf Therapeutics in Q2 2024 and held it in 1 quarter.
  • Murchinson's Werewolf Therapeutics position peaked at $153K in Q2 2024.
  • 69 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q3 2024.

Based on Murchinson's 13F filing for Q3 2024, filed 14 Nov 2024.